Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib in NSCLC with Uncommon EGFR Mutations
NCT04504071Phase 2Active, not recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Dec 2020
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective Response Rate. Started Dec 2020; status: active, not recruiting.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04504071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504071.